We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time -0:00
1x
Chapters
descriptions off, selected
captions and subtitles off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
Ian E. Krop, MD, PhD, associate chief of the division of breast oncology in the Susan F. Smith Center for Women's Cancersat Dana-Farber Cancer Institute, spoke with Healio about recent findings from the DESTINY-Breast03 trial.
Researchers presented the findings at this year’s San Antonio Breast Cancer Symposium.
“This was a very large, randomized trial comparing trastuzumab deruxtecan vs. the previous second line standard, which is [ado-trastuzumab emtansine (T-DM1)], and we’d already seen in previous presentations that trastuzumab deruxtecan had superior progression-free survival compared [with] T-DM1,” Krop said, adding that the updated results showed that trastuzumab deruxtecan was superior in all examined subsets.
“What was particularly interesting in this presentation was that, looking at the patients who had previously had brain metastases at baseline, again, [trastuzumab deruxtecan] looked far superior to T-DM1, and a substantial fraction of patients actually had intercranial responses to trastuzumab deruxtecan,” said Krop.
He explained that this is important in patients with HER2-positive breast cancers because brain metastases are common in this subset.
“I think there’s hope for patients with HER2-positive brain metastases that [antibody drug conjugates] like trastuzumab deruxtecan could be active in that particular area,” Krop said.
Reference:
Hurvitz S, et al. Abstract GS3-01. Presented at: San Antonio Breast Cancer Symposium; Dec. 7-10, 2021; San Antonio.
